Drug Trial Radar · NCT07948122
Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,290
Planned (sponsor's estimate)
Start
Jan 4, 2027
Primary completion
Dec 31, 2035
Study completion Dec 31, 2037
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The treatment of younger AML patients fit for intensive chemotherapy (IC) has long been based on a combination of an anthracycline and cytarabine as induction, followed by high-dose cytarabine (HDAC) consolidation, and possibly allogeneic stem-cell transplantation at least in non-favorable risk AML patients. Even if new agents like gemtuzumab ozogamicin (GO), FLT3 inhibitors, or CPX-351 have been approved to treat some patient subsets, there has been no major therapeutic advances to date in this field. The first multicenter trial from the ALFA-FILO intergroup (Backbone InterGroup trial-1, BIG-1; NCT02416388; PHRC2010-03) randomly explored various standard intensive chemotherapy strategies, including higher-dose idarubicin vs. high-dose daunorubicin (DNR) and intermediate-dose cytarabine (IDAC) vs. HDAC in patients (18-60 years) with newly-diagnosed AML. This first part of the study, which enrolled 1405 participants between 01/2015 and 05/2019, showed that the benefit/risk ratio favored high-dose DNR for remission induction and IDAC consolidation, establishing the national standard treatment for younger AML patients. Six-year OS was 53.4% showing that there is still considerable room for improvement in this younger patient population. High-throughput sequencing and multiparametric flow cytometry have significantly improved prognostic classifications and the evaluation of response to therapy through the quantification of measurable residual disease (MRD). Many studies have shown that the higher the MRD, the higher the risk of relapse and death; and recent guidelines have included MRD in the response criteria. Achieving complete remission without MRD is a major goal after first-line treatment to guide subsequent treatments, including transplantation. Furthermore, MRD follow-up in patients who achieved complete remission is becoming a major issue, as patients treated for molecular relapse appear to have a better prognosis than patients treated for morphological relapse. Preliminary data also showed encouraging results from salvage treatment at the time of MRD relapse. Quizartinib (a second-generation FLT3-ITD inhibitor) and venetoclax (the first-in-class BCL-2 inhibitor) have been recently approved for the treatment of AML. Quizartinib was approved on the basis of a placebo-controlled trial but its added value compared to midostaurin (first FLT3 inhibitor available in this indication since 2018) has never been prospectively explored. Although venetoclax was approved for first line therapy of patients who are unfit for intensive chemotherapy, it is widely used in relapsed or refractory younger patients. Venetoclax combined with intensive salvage chemotherapy is feasible and induce a high rate of CR. However, no prospective, randomized trial demonstrated venetoclax efficacy in this setting.
Conditions
- Acute Myeloid Leukemia
Interventions
QuizartinibDrug
Sub-study 1 : addition of quizartinib to induction chemotherapy (7+3) and to consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.
MidostaurinDrug
Sub-Study 1: Addition of midostaurin to induction chemotherapy (7+3) and consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.
VenetoclaxDrug
Sub-Study 2 : Addition of venetoclax to high-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.
High-dose cytarabineDrug
High-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sub-Study 1 : MRD responseTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Sub-Study 2 : MRD response venetoclaxTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Sub-Study 3 : Overall survivalTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 53 months
Locations
55 sites in 1 country. Site status is shown where the registry gives one.
CHU d'Amiens
Amiens, France, France
CHU d'Angers
Angers, France, France
CH Argenteuil
Argenteuil, France, France
CHR de Metz-Thionville
Ars-Laquenexy, France, France
CH Avignon
Avignon, France, France
CH de Bayonne
Bayonne, France, France
CHU de Besançon
Besançon, France, France
CH de Béziers
Béziers, France, France
CH d'Avicenne
Bobigny, France, France
CHU de Brest
Brest, France, France
CHU de Caen
Caen, France, France
CH de Chambéry
Chambéry, France, France
Hôpital Clamart Percy
Clamart, France, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France, France
CH de Corbeil
Corbeil-Essonnes, France, France
CH de Créteil
Créteil, France, France
CHU de Dijon
Dijon, France, France
CH de Dunkerque
Dunkirk, France, France
CH Annecy Genevois
Épagny, France, France
CHU de Grenoble
Grenoble, France, France
CH de Versailles
Le Chesnay, France, France
CH de Lens
Lens, France, France
Hôpital Saint Vincent de Paul
Lille, France, France
CHU de Lille
Lille, France, France
CHU de Limoges
Limoges, France, France
Centre Léon Bérard
Lyon, France, France
CHU de Marseille
Marseille, France, France
Institut Paoli Calmettes
Marseille, France, France
CH de Meaux
Meaux, France, France
CHU de Montpellier
Montpellier, France, France
CH de Mulhouse
Mulhouse, France, France
CHU de Nantes
Nantes, France, France
CHU de Nice
Nice, France, France
CHU de Nîmes
Nîmes, France, France
CHU d'Orléans
Orléans, France, France
Institut Curie
Paris, France, France
Hôpital Saint-Louis
Paris, France, France
Hôpital de la Pitié Salpêtrière
Paris, France, France
Hôpital Cochin
Paris, France, France
Hôpital Necker
Paris, France, France
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.